Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated June 2026 · ClinicalTrials.gov

Chinese PLA General Hospital

Reviewed by TrialFinderData Editorial Team · Updated

17 clinical trials · 17 recruiting · OTHER

Chinese PLA General Hospital has 17 clinical trials registered on ClinicalTrials.gov, with 17 actively recruiting participants. The trials listed below cover 20 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About Chinese PLA General Hospital\'s Trial Portfolio

Chinese PLA General Hospital is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

17 of Chinese PLA General Hospital's 17 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

Chinese PLA General Hospital's research footprint spans Papillary Thyroid Cancer (2 trials), relapsed-refractory-acute-myeloid-leukemia (1), and non-hodgkin-s-lymphoma (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

is the largest single phase in Chinese PLA General Hospital's portfolio at 41% of registered trials. The full phase breakdown appears in the sidebar.

Trials by Chinese PLA General Hospital

RECRUITINGPhase 2NCT06084819

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

The purpose of this study is to compare the efficacy and safety of venetoclax combined with CACAG regimen with BAT regimen in the treatment of relapsed/refractory acute myeloid...

Sponsor: Chinese PLA General HospitalEnrolling: 2001 location
Relapsed/Refractory Acute Myeloid Leukemia
RECRUITINGPhase 1 / Phase 2NCT06014073

TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL

ATHENA chimeric antigen receptor (CAR)-T, a CD19-directed CAR-T cell immunotherapy comprised of allogeneic T cells prepared for the treatment of relapsed or refractory (r/r)...

Sponsor: Chinese PLA General HospitalEnrolling: 303 locations
Non Hodgkin's Lymphoma
RECRUITINGPhase 2NCT05833893

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

Patients with newly diagnosed, pathologically confirmed NK/T-cell lymphoma of stage III-IV treated with XCOPL regimen. 3 weeks for a cycle, with a total of 6-8 cycles.

Sponsor: Chinese PLA General HospitalEnrolling: 101 location
nk/T-cell LymphomaNewly DiagnosedAdvanced Lymphoma
RECRUITINGNCT06559761

Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research

Hepatocellular carcinoma (HCC) is a highly heterogeneous malignant tumor with significant differences in invasion, proliferation ability and patient prognosis. Currently, there is...

Sponsor: Chinese PLA General HospitalEnrolling: 5001 location
Hepatocellular Carcinoma Stage III
RECRUITINGPhase 1NCT07018518

PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma

In this single-center,open-label, phase I study, the safety and efficacy of PIN in combination with programmed cell death protein antibody (anti-PD1) therapeutic regimen will be...

Sponsor: Chinese PLA General HospitalEnrolling: 251 location
Hepatocellular CarcinomaAdult
RECRUITINGEarly Phase 1NCT07645690

The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma

CLEAR CAR-T cell injection (ET-970) is an engineered CD70-targeting allogeneic Chimeric Antigen Receptor T-Cell (CAR-T cell). This is a multi-center, single-arm, open-label, early...

Sponsor: Chinese PLA General HospitalEnrolling: 303 locations
Unresectable or Metastatic Clear Cell Renal Cell Carcinoma
RECRUITINGNCT06733740

Ultrasound-guided Thermal Ablation for Papillary Thyroid Carcinoma

To evaluate long-term outcomes of ultrasound-guided thermal ablation for the treatment of papillary thyroid carcinoma

Sponsor: Chinese PLA General HospitalEnrolling: 30001 location
Papillary Thyroid Cancer
RECRUITINGNCT06316895

The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma

1. To evaluate the clinical outcomes of ultrasound-guided thermal ablation and thyroid surgery for the treatment of papillary thyroid carcinoma; 2. To develop and validate a...

Sponsor: Chinese PLA General HospitalEnrolling: 37721 location
Papillary Thyroid Cancer
RECRUITINGNCT06340945

The Outcomes of Ultrasound-guided Thermal Ablation for Benign Thyroid Nodules

1. To evaluate the clinical outcomes of ultrasound-guided thermal ablationfor the treatment of benign thyroid nodules; 2. To develop and validate a artificial intelligence model...

Sponsor: Chinese PLA General HospitalEnrolling: 15001 location
Thyroid Nodules
RECRUITINGNCT06729762

Ultrasound-guided Thermal Ablation for Benign Thyroid Nodules

To evaluate long-term outcomes of ultrasound-guided thermal ablation for benign thyroid nodules

Sponsor: Chinese PLA General HospitalEnrolling: 15001 location
Thyroid Nodule (Benign)
RECRUITINGNCT06733766

Ultrasound-guided Thermal Ablation for Recurrent Thyroid Cancer

To evaluate the long-term outcomes of ultrasound-guided thermal ablation for recurrent thyroid cancer

Sponsor: Chinese PLA General HospitalEnrolling: 3001 location
Recurrent Thyroid Cancer
RECRUITINGPhase 3NCT04483076

Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer

RESONANCE-II trial is a prospective, multicenter, randomized, controlled phase III study which will enroll 524 patients in total. Patients with eligibility will be registered,...

Sponsor: Chinese PLA General HospitalEnrolling: 5241 location
Gastric CancerChemotherapy Effect
RECRUITINGPhase 1NCT07620275

Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA

KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This multicenter, single-arm, open-label, early exploratory clinical study is...

Sponsor: Chinese PLA General HospitalEnrolling: 93 locations
Multiple Myeloma
RECRUITINGPhase 1 / Phase 2NCT07635758

Human Placenta-derived 3D Mesenchymal Stem Cells(Guojianqingke)

This is a Phase I/IIa clinical trial evaluating human placental-derived 3D mesenchymal stem cell (MSC) injection in patients with acute ischemic stroke (AIS). Phase I is a...

Sponsor: Chinese PLA General HospitalEnrolling: 241 location
Acute Ischemic Stroke
RECRUITINGNCT07394959

Hydration Guided by Remote Dielectric Sensing (ReDS) System for Preventing Acute Kidney Injury in Elderly Patients With...

Explore the effectiveness and safety of tailored hydration guided by lung water index monitor system for prevention of acute kidney injury after percutaneous coronary intervention...

Sponsor: Chinese PLA General HospitalEnrolling: 3201 location
Coronary Artery DiseaseChronic Kidney DiseaseElderly
RECRUITINGNCT07072858

Using Cardiac MRI to Predict Outcomes in Patients With STEMI

This prospective, multicenter observational study aims to evaluate the prognostic value of a comprehensive set of cardiac magnetic resonance (CMR) imaging parameters in patients...

Sponsor: Chinese PLA General HospitalEnrolling: 10001 location
Myocardial Infarction (MI)ST Segment Elevation Myocardial Infarction (STEMI)Magnetic Resonance Imaging (MRI)+4
RECRUITINGNCT07009873

Clinical Application of Wearable Ultrasound Sensors

This study aims to develop and evaluate a wearable ultrasound imaging sensor for the early diagnosis and real-time monitoring of various diseases, such as cardiovascular...

Sponsor: Chinese PLA General HospitalEnrolling: 3001 location
DVT - Deep Vein ThrombosisPOCUS

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does Chinese PLA General Hospital have on ClinicalTrials.gov?

Chinese PLA General Hospital has 17 clinical trials registered on the federal ClinicalTrials.gov registry, of which 17 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does Chinese PLA General Hospital study?

Chinese PLA General Hospital's registered trials cover 20 conditions on ClinicalTrials.gov, led by Papillary Thyroid Cancer (2 trials), relapsed-refractory-acute-myeloid-leukemia (1 trial), non-hodgkin-s-lymphoma (1 trial), nk-t-cell-lymphoma (1 trial), newly-diagnosed (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a Chinese PLA General Hospital clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-06-26 · 17 trials tracked for Chinese PLA General Hospital.